Press Releases April 15, 2026 08:00 PM

Navitas Semiconductor to Report Q1 2026 Financial Results on Tuesday, May 5, 2026

Navitas Semiconductor announces Q1 2026 earnings release and conference call schedule for May 5, 2026.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
NVTS

Navitas Semiconductor will report its first quarter 2026 financial results on May 5, 2026, after market close. The company will host a conference call with executives to discuss results and business outlook. Navitas specializes in advanced power semiconductor technologies such as gallium nitride (GaN) and silicon carbide (SiC) for applications across AI data centers, performance computing, energy and grid infrastructure, and industrial electrification.

Navitas Semiconductor to Report Q1 2026 Financial Results on Tuesday, May 5, 2026
NVTS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Navitas Semiconductor to report Q1 2026 financial results on May 5, after market close.
  • Conference call hosted by CEO and CFO scheduled to discuss results and outlook.
  • Company focuses on innovative power semiconductor technologies including GaN and SiC impacting sectors like AI, energy, and industrial electrification.


TORRANCE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS) today announced that it will report first quarter 2026 financial results on Tuesday, May 5, 2026, after the market close.

Navitas’ President and CEO, Chris Allexandre, and CFO, Tonya Stevens, will host a conference call at 2:00 p.m. Pacific Time to discuss the Company’s financial results and business outlook.

Analysts and investors are invited to join the conference call using the following information:

When: Tuesday, May 5, 2026
Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)
Toll Free Dial-in: 1-800-715-9871 or 646-307-1963
Conference ID: 5910273
Webcast and Slides: Click Here

Additionally, a live and archived audio webcast of the conference call as well as supporting presentation materials will be accessible from the Investor Relations section of the Company’s website at ir.navitassemi.com.

About Navitas

Navitas Semiconductor (Nasdaq: NVTS) is a next-generation power semiconductor leader in gallium nitride (GaN) and IC integrated devices, and high-voltage silicon carbide (SiC) technology, driving innovation across AI data centers, performance computing, energy and grid infrastructure, and industrial electrification. With more than 30 years of combined expertise in wide bandgap technologies, GaNFast™ power ICs integrate GaN power, drive, control, sensing, and protection, delivering faster power delivery, higher system density, and greater efficiency. GeneSiC™  high-voltage SiC devices leverage patented trench-assisted planar technology to provide industry-leading voltage capability, efficiency, and reliability for medium-voltage grid and infrastructure applications. Navitas has over 300 patents issued or pending and is the world’s first semiconductor company to be CarbonNeutral®-certified.

Navitas Semiconductor, GaNFast, GaNSense, GeneSiC, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited and affiliates. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Investor Relations Contacts:

Shelton Group
Leanne Sievers | Brett Perry
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/27deee9e-bcc1-424a-bcba-deff33083551


Risks

  • Financial results may not meet market expectations impacting stock price.
  • Shifts in demand across targeted sectors like AI data centers or energy infrastructure could affect future performance.
  • Competition in semiconductor technology sectors could pressure Navitas's market share and profitability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026